Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats.

Zhang Y, Zhang J, Wang Q, Lei X, Chu Q, Xu GT, Ye W

Investigative ophthalmology & visual science5 Jan 2011Cited by 78 (Europe PMC)

PMID20688733DOI10.1167/iovs.09-4727PepBankPUB-20688733

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats, E4a prevented the diabetes-associated reduction in retinal b-wave amplitude versus saline-treated diabetic rats.
In plain wordsIn rats, E4a prevented reduced retinal b-wave amplitude compared with saline-treated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseRetinal b-wave amplitude
Study
ratn: not reported in source
streptozotocin-induced diabetic Sprague-Dawley rats
Comparator
saline-treated diabetic rats
Outcome group
Neuroprotection · Eye
Source sentences
Summary
E4a prevented the reduction in b-wave amplitude and oscillatory potential amplitude caused by diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a).
Summary · context
Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068873301
02AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats, E4a prevented the diabetes-associated reduction in oscillatory potential amplitude versus saline-treated diabetic rats.
In plain wordsIn rats, E4a prevented reduced retinal oscillatory potential amplitude compared with saline-treated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOscillatory potential amplitude
Study
ratn: not reported in source
streptozotocin-induced diabetic Sprague-Dawley rats
Comparator
saline-treated diabetic rats
Outcome group
Neuroprotection · Eye
Source sentences
Summary
E4a prevented the reduction in b-wave amplitude and oscillatory potential amplitude caused by diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a).
Summary · context
Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068873302
03AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats, E4a prevented outer nuclear layer cell loss versus saline-treated diabetic rats.
In plain wordsIn rats, E4a prevented loss of outer retinal nuclear layer cells compared with saline-treated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseOuter nuclear layer cell loss
Study
ratn: not reported in source
streptozotocin-induced diabetic Sprague-Dawley rats
Comparator
saline-treated diabetic rats
Outcome group
Neuroprotection · Eye
Source sentences
Summary
It also prevented the cell loss of outer nuclear layer and inner nuclear layer;
2 context sentences(design, population, supporting numbers)
Summary · context
Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a).
Summary · context
Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068873303
04AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats, E4a prevented inner nuclear layer cell loss versus saline-treated diabetic rats.
In plain wordsIn rats, E4a prevented loss of inner retinal nuclear layer cells compared with saline-treated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInner nuclear layer cell loss
Study
ratn: not reported in source
streptozotocin-induced diabetic Sprague-Dawley rats
Comparator
saline-treated diabetic rats
Outcome group
Neuroprotection · Eye
Source sentences
Summary
It also prevented the cell loss of outer nuclear layer and inner nuclear layer;
2 context sentences(design, population, supporting numbers)
Summary · context
Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a).
Summary · context
Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068873304
05AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism
In diabetic rats, E4a reduced retinal glutamate versus saline-treated diabetic rats.
In plain wordsIn rats, E4a reduced retinal glutamate compared with saline-treated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseRetinal glutamate
Study
ratn: not reported in source
streptozotocin-induced diabetic Sprague-Dawley rats
Comparator
saline-treated diabetic rats
Outcome group
Neuroprotection · Eye
Source sentences
Summary
The concentration of glutamate in the retina was higher in diabetic rats and was significantly reduced in the E4a-treated group.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a).
Summary · context
Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068873305
06AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism
In diabetic rats, E4a increased retinal GLP-1R expression versus saline-treated diabetic rats.
In plain wordsIn rats, E4a increased retinal GLP-1 receptor expression compared with saline-treated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseRetinal GLP-1R expression
Study
ratn: not reported in source
streptozotocin-induced diabetic Sprague-Dawley rats
Comparator
saline-treated diabetic rats
Outcome group
Receptor activity and mechanism · Eye
Source sentences
Summary
Consistent with such changes, retinal GLP-1R and GLAST expression were reduced in the diabetic retina but upregulated in E4a-treated rats.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a).
Summary · context
Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068873306
07AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism
In diabetic rats, E4a increased retinal GLAST expression versus saline-treated diabetic rats.
In plain wordsIn rats, E4a increased retinal GLAST expression compared with saline-treated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseRetinal GLAST expression
Study
ratn: not reported in source
streptozotocin-induced diabetic Sprague-Dawley rats
Comparator
saline-treated diabetic rats
Outcome group
Receptor activity and mechanism · Eye
Source sentences
Summary
Consistent with such changes, retinal GLP-1R and GLAST expression were reduced in the diabetic retina but upregulated in E4a-treated rats.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a).
Summary · context
Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068873307
08AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats, E4a did not improve retinal functional parameters at 3 months versus saline-treated diabetic rats.
In plain wordsIn rats, E4a did not improve retinal function at 3 months compared with saline-treated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeRetinal function at 3 months
Study
ratn: not reported in source
streptozotocin-induced diabetic Sprague-Dawley rats
Comparator
saline-treated diabetic rats
Outcome group
Neuroprotection · Eye
Source sentences
Summary
No improvement was found in the retina in both functional and morphologic parameters 3 months after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a).
Summary · context
Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068873308
09AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats, E4a did not improve retinal morphologic parameters at 3 months versus saline-treated diabetic rats.
In plain wordsIn rats, E4a did not improve retinal structure at 3 months compared with saline-treated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeRetinal morphology at 3 months
Study
ratn: not reported in source
streptozotocin-induced diabetic Sprague-Dawley rats
Comparator
saline-treated diabetic rats
Outcome group
Neuroprotection · Eye
Source sentences
Summary
No improvement was found in the retina in both functional and morphologic parameters 3 months after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a).
Summary · context
Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068873309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats.

Summary

Results from this study9

Studies that did not test the peptide alone9

Version history

Subjects

Publication types

MeSH terms